Cancer treatment associated cardiac toxicities


  • Eric Y. Chang Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
  • Aneese F. Chaudhry Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
  • Victoria Lopez Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA
  • Sanjay R. Jain Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA



Cardiac toxicity, Chemotherapy, Cancer


Cardiovascular disease remains the leading cause of mortality and morbidity in men and women both in the US and worldwide. With increased access to healthcare, it is predicted that life expectancies in developed countries will continue to rise and thus, lead to an increase in both cardiovascular disease and cancer. Similarly, improved survival rates in cancer patients have led to an increased awareness of the presence and potential worsening of cardiovascular disease in these patients. Cardiovascular complications due to side effects from cancer therapy or from cancer progression can be a common occurrence. Although recent advances in cancer therapeutics have led to improved survival rates and quality of life, the increase in life expectancy may be counteracted by the increased morbidity and mortality from progressive cardiac pathology. Examples of such complications include local invasion or distant metastatic spread, which can lead to superior vena cava syndrome, cardiac tamponade, or hyperviscosity syndromes. In addition, many chemo and radiation therapies can be directly toxic to the cardiovascular system. This review aims to discuss the potential cardiac toxicities of the most commonly used chemotherapeutics along with some strategies to manage these complex patients.


Cardiotoxicity of cancer therapy. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. J Clin Oncol. 2005;23(30):7685.

Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010;144(1):3.

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. Journal of Clinical Oncology. 2002;20(5):1215-21.

Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710.

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(7):vii155-66.

Steinherz LJ, Steinherz PG, Tan CT. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672-7.

Mimnaugh EG, Trush MA, Bhatnagar. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol. 1985;34:847-56.

Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987;19:817-28.

Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007 Sept 15;67(18):8839-46.

Doxorubicin cardiotoxicity: Analysis of prevailing hypothesis. Olson RD, Mushlin PS. FASEB J. 1990;4:3076-86.

Tokarska-Schlattner M, Zaugg M, Zuppinger C. New insights into doxorubicin-induced cardiotoxicity. The critical role of cellular energetics. J Mol Cell Cardiol 2006;41:389-405.

Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun;82(6):1109-18.

Ganz WI, Sridhar KS, Ganz SS. Review of Tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-70.

Machado V, Cabral A, Monteiro P. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev. Port. Cardiol. 2008;27:1277-96.

Feuerstein G, Yue TL, Ma X. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovas Dis. 1998;41:17-24.

Labianca R, Beretta G, Clerici M. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori. 1982;68:505

Anand AJ. Fluorouracil cardiotoxicity. Ann Pharmacother. 1994;28:374.

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-47.

Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191.

Shoemaker L, Arora U, Rocha Lima C. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11:46-9.

Sudhoff T, Enderle M, Pahlke M. 5-fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661-4.

Madeddu C, Deidda M, Piras A. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. Journal of Cardiovascular Medicine. 2016;17:12-218.

Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol. 1980;30:871-9.

Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer. 1988;61:36-45.

Saif MW, Quinn MG, Thomas RR, Ernst A, Grem JL. Cardiac toxicity associated with capecitabine therapy. Acta Oncol. 2003;42(4):342-4.

Johannes JM, Lieke HJ, Linda M. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. European Journal of Cancer. 2017;76:63-9.

Ritchie DS, Seymour JF, Roberts AW. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation. 2001;28:1:101-3.

Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95(7):1592.

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22(2):322.

Fiúza M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther. 2009;26(1):S9.

Martel S, Maurer C, Lambertini M. Breast cancer treatment-induced cardiotoxicity. Expert Opinion on Drug Safety. 2017;16:9:1021-38.

Serie DJ, Crook JE, Necela BM. Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenetics and Genomics. 2017;27:378-85.

Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900

Narahara KA, Singer JW, Ritchie JL. Time- and dose-dependent changes in ejection fraction after anthracycline therapy. J Cardiovasc Pharmacol. 1979;1:395-401.

Yu AF, Mukku RB, Verma S. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Breast Cancer Research and Treatment. 2017;1-7.

Swain SM, Ewer MS, Cortes J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in Cleopatra: a randomized, double-blind, placebo-controlled phase III study. Oncologist. 2013;18:257.

Gianni L, Pienkowski T, Im YH. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25-32.

Von Minckwiz G, Procter M, de Azambuja E. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med [Internet]. 2017.

Daily MED - PERJETA- Pertuzumab Injection, Solution Concentrate. U.S. National Library of Medicine. National Institutes of Health, 19 Dec 2017. Available at:

Rosa GM, Gigli L, Tagliasacchi MI. Update on cardiotoxicity of anti-cancer treatments. European Journal of Clinical Investigation. 2016;46:3:264-84.

Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin. 2013 Aug;29(8):1015-24.

Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008 Jun;83(6):679-86.

Narayan V, Keefe S, Haas N. Prospective evaluation of sunitinib-induced cardiotoxicity in patients with metastatic renal cell carcinoma. Clinical Cancer Research. 2017;23:14:3601-9.

Chu TF, Rupnick MA, Kerkela R. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;270(9604):2011-9.

Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9.




How to Cite

Chang, E. Y., Chaudhry, A. F., Lopez, V., & Jain, S. R. (2018). Cancer treatment associated cardiac toxicities. International Journal of Basic & Clinical Pharmacology, 7(3), 353–358.



Review Articles